Abzena PLC Notice of AGM (7440Y)
23 Agosto 2018 - 5:48PM
UK Regulatory
TIDMABZA
RNS Number : 7440Y
Abzena PLC
23 August 2018
Abzena plc
Notice of AGM
Cambridge, UK, 23 August 2018 - Abzena plc (AIM: ABZA, 'Abzena'
or the 'Group'), a life sciences group providing services and
technologies to enable development and manufacture of
biopharmaceutical products, announces that its Annual General
Meeting (AGM) will be held at 10:00am on Monday, 17 September 2018
at the offices of Pinsent Masons LLP, 30 Crown Place, Earl Street,
London, EC2A 4ES.
A copy of the Notice of AGM, Form of Proxy, and 2018 Annual
Report are available at
http://www.abzena.com/about/investor-information/documents/
-Ends-
Enquiries:
Abzena plc
John Burt, Chief Executive Officer Julian
Smith, Chief Financial Officer +44 1223 903498
Numis (Nominated Adviser and Broker)
James Black / Paul Gillam / Duncan Monteith +44 20 7260 1000
N+1 Singer (Joint Broker)
Aubrey Powell / Liz Yong +44 20 7496 3000
Instinctif Partners +44 20 7457 2020
Melanie Toyne Sewell / Rozi Morris / abzena@instinctif.com
Alex Shaw
Notes to Editors
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and
complementary services to enable the development and manufacture of
biopharmaceutical products.
The term 'ABZENA Inside' is used by Abzena to describe products
that have been created using its proprietary technologies and are
being developed by its partners, and include Composite Human
Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs).
Abzena has the potential to earn future licence fees, milestone
payments and/or royalties on ABZENA Inside products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA):
-- Biology research studies, including immunogenicity assessment
of candidate biopharmaceutical products and bioassay
development;
-- Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;
-- Cell line development for the manufacture of recombinant proteins and antibodies;
-- Contract process development and GMP manufacture of
biopharmaceuticals, including monoclonal antibodies and recombinant
proteins for preclinical and clinical studies;
-- Contract synthetic chemistry and bioconjugation research
services, focused on antibody-drug conjugates (ADCs);
-- Proprietary site-specific conjugation technologies and novel payloads for ADC development;
-- GMP manufacturing of ADC linkers, payloads & combined linker-payloads; and
-- GMP analytical services for biopharmaceutical manufacturing projects.
For more information, please see www.abzena.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NOASEMFIDFASELA
(END) Dow Jones Newswires
August 23, 2018 11:48 ET (15:48 GMT)
Grafico Azioni Abzena (LSE:ABZA)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Abzena (LSE:ABZA)
Storico
Da Giu 2023 a Giu 2024